Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma

Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.

Related Keywords

,European Commission ,Servier Pharmaceuticals As Tibsovo ,Servier Pharmaceuticals ,Acute Myeloid Leukemia ,Blood Cancer ,Chemotherapy ,Targeted Therapy ,Cholangiocarcinoma ,